Outlook Therapeutics is trading 5.48% higher at $0.59 on October 9, 2026; available reporting has not identified a specific reason for the intraday gain. - The company named Greg DiPasquale chief commercial officer, expanding his role as it prepares for a U.S. launch of LYTENAVA by year-end. - The broader market and biotech sector are also higher, offering a possible supportive backdrop. The announcement did not explicitly link the appointment to the share-price move.